Combined Support-Vector-Machine-Based Virtual Screening and Docking Method for the Discovery of IMP-1 Metallo-β-Lactamase Inhibitors Supplementary Data

Metallo-β-lactamases can hydrolyze a broad range of β-lactam antibiotics and no effective inhibitors could be used in the clinic. Therefore, the discovery of metallo-β-lactamase inhibitors has attracted much attention in recent years. In this study, a support vector machine (SVM) that separates compounds into positives and negatives, combined with docking method was employed for virtual screening of IMP-1 metallo-β-lactamase inhibitors. Eight of the twenty five selected compounds were purchased for in vitro assays. Among them, four compounds show inhibitory potency against IMP-1. Two of them are found to have novel scaffolds, implying a good potential for further optimization.

[1]  Jürgen Pleiss,et al.  Insight into the mechanism of the IMP-1 metallo-beta-lactamase by molecular dynamics simulations. , 2003, Protein engineering.

[2]  H. Morishima,et al.  Carbapenem derivatives as potential inhibitors of various beta-lactamases, including class B metallo-beta-lactamases. , 1999, Antimicrobial agents and chemotherapy.

[3]  Jorng-Tzong Horng,et al.  Incorporating support vector machine for identifying protein tyrosine sulfation sites , 2009, J. Comput. Chem..

[4]  Jorng-Tzong Horng,et al.  Incorporating structural characteristics for identification of protein methylation sites , 2009, J. Comput. Chem..

[5]  Xiuzhen Hu,et al.  Using support vector machine to predict β‐ and γ‐turns in proteins , 2008, J. Comput. Chem..

[6]  Y. Yamagata,et al.  Irreversible inhibition of metallo-beta-lactamase (IMP-1) by 3-(3-mercaptopropionylsulfanyl)propionic acid pentafluorophenyl ester. , 2005, Angewandte Chemie.

[7]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[8]  Hanbing Rao,et al.  Identification of small molecule aggregators from large compound libraries by support vector machines , 2009, J. Comput. Chem..

[9]  Yu Chen,et al.  Virtual screening prediction of new potential organocatalysts for direct aldol reactions , 2010 .

[10]  Rie Nagano,et al.  Carbapenem Derivatives as Potential Inhibitors of Various β-Lactamases, Including Class B Metallo-β-Lactamases , 1999, Antimicrobial Agents and Chemotherapy.

[11]  Lars Olsen,et al.  New leads of metallo-beta-lactamase inhibitors from structure-based pharmacophore design. , 2006, Bioorganic & medicinal chemistry.

[12]  Heng Zheng,et al.  Docking-based 3D-QSAR modeling of the inhibitors of IMP metallo-β-lactamase , 2012, Medicinal Chemistry Research.

[13]  S. Siemann,et al.  N-Arylsulfonyl Hydrazones as Inhibitors of IMP-1 Metallo-β-Lactamase , 2002, Antimicrobial Agents and Chemotherapy.

[14]  X. H. Liu,et al.  Virtual Screening of Abl Inhibitors from Large Compound Libraries by Support Vector Machines , 2009, J. Chem. Inf. Model..

[15]  S. Siemann,et al.  Thiols as classical and slow-binding inhibitors of IMP-1 and other binuclear metallo-beta-lactamases. , 2003, Biochemistry.

[16]  Zhide Hu,et al.  A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site. , 2008, European journal of medicinal chemistry.

[17]  Rong Wang,et al.  Evaluation of Virtual Screening Performance of Support Vector Machines Trained by Sparsely Distributed Active Compounds. , 2008 .

[18]  Lars Hemmingsen,et al.  Docking and scoring of metallo-β-lactamases inhibitors , 2004, J. Comput. Aided Mol. Des..

[19]  J. Frère,et al.  Structural basis for the broad-spectrum inhibition of metallo-beta-lactamases by thiols. , 2008, Organic & biomolecular chemistry.

[20]  S. Siemann,et al.  N-arylsulfonyl hydrazones as inhibitors of IMP-1 metallo-beta-lactamase. , 2002, Antimicrobial Agents and Chemotherapy.

[21]  Jürgen Pleiss,et al.  Insight into the mechanism of the IMP-1 metallo-β-lactamase by molecular dynamics simulations , 2003 .

[22]  Cheryl A. Janson,et al.  Identification of a Series of Tricyclic Natural Products as Potent Broad-Spectrum Inhibitors of Metallo-β-Lactamases , 2002, Antimicrobial Agents and Chemotherapy.

[23]  T. Sawai,et al.  Amino Acid Substitutions in a Variant of IMP-1 Metallo-β-Lactamase , 2000, Antimicrobial Agents and Chemotherapy.

[24]  N. Sharma,et al.  Succinic Acids as Potent Inhibitors of Plasmid-borne IMP-1 Metallo-β-lactamase* , 2001, The Journal of Biological Chemistry.

[25]  Xiangdong Gao,et al.  A common binding mode that may facilitate the design of novel broad-spectrum inhibitors against metallo-β-lactamases , 2013, Medicinal Chemistry Research.

[26]  Pierre Tufféry,et al.  A fast method for large‐scale De Novo peptide and miniprotein structure prediction , 2009, J. Comput. Chem..

[27]  Xin Chen,et al.  Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking , 2011, J. Chem. Inf. Model..

[28]  J. Frère,et al.  Standard numbering scheme for class B beta-lactamases. , 2001, Antimicrobial agents and chemotherapy.

[29]  Y Z Chen,et al.  Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. , 2010, Molecular pharmaceutics.

[30]  J. Frère,et al.  Inhibitors of the FEZ-1 metallo-beta-lactamase. , 2007, Bioorganic & medicinal chemistry letters.

[31]  T. Spicer,et al.  Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. , 2009, Bioorganic & medicinal chemistry.

[32]  Hui Chen,et al.  Inhibitor Discovery of Full-Length New Delhi Metallo-β-Lactamase-1 (NDM-1) , 2013, PloS one.

[33]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[34]  Jian-Ping Zhou,et al.  Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met. , 2011, European journal of medicinal chemistry.

[35]  Y. Yamagata,et al.  Probing, Inhibition, and Crystallographic Characterization of Metallo‐β‐lactamase (IMP‐1) with Fluorescent Agents Containing Dansyl and Thiol Groups , 2006, ChemMedChem.

[36]  Y Z Chen,et al.  Identifying Novel Type ZBGs and Nonhydroxamate HDAC Inhibitors Through a SVM Based Virtual Screening Approach , 2010, Molecular informatics.

[37]  T. Kudo,et al.  Metallo-beta-lactamase inhibitory activity of phthalic acid derivatives. , 2009, Bioorganic & medicinal chemistry letters.

[38]  Xiangdong Gao,et al.  β-Lactamase inhibitors: an update. , 2013, Mini reviews in medicinal chemistry.

[39]  J. Frère,et al.  Competitive Inhibitors of the CphA Metallo-β-Lactamase from Aeromonas hydrophila , 2007, Antimicrobial Agents and Chemotherapy.

[40]  Y. Yamaguchi,et al.  Comparative study of the inhibition of metallo-beta-lactamases (IMP-1 and VIM-2) by thiol compounds that contain a hydrophobic group. , 2004, Biological & pharmaceutical bulletin.

[41]  R. Ambler,et al.  The structure of beta-lactamases. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[42]  Hsien-Da Huang,et al.  N‐Ace: Using solvent accessibility and physicochemical properties to identify protein N‐acetylation sites , 2010, J. Comput. Chem..

[43]  B. Leiting,et al.  Inhibition of IMP-1 metallo-beta-lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives. , 1999, FEMS microbiology letters.

[44]  N. Strynadka,et al.  Cyclobutanone analogues of beta-lactams revisited: insights into conformational requirements for inhibition of serine- and metallo-beta-lactamases. , 2010, Journal of the American Chemical Society.

[45]  Xue-Gang Yang,et al.  In silico prediction and screening of γ‐secretase inhibitors by molecular descriptors and machine learning methods , 2009, J. Comput. Chem..

[46]  D. Vanderwall,et al.  Structure-activity relationships of biphenyl tetrazoles as metallo-β-lactamase inhibitors , 1999 .

[47]  Moreno Galleni,et al.  Standard Numbering Scheme for Class B β-Lactamases , 2001, Antimicrobial Agents and Chemotherapy.